Sell-side research analysts give opinions on future stock movement for Trinity Biotech plc (NASDAQ:TRIB). These opinions are based on extensive research and deep knowledge of the company. Analysts taken into consideration by Thomson Reuters have created a consensus target price of $8.50 on the stock. Target prices may differ from one analyst to another due to the ways they go about calculating future price targets.
After a recent check on the stock, shares have been seen trading $0.04 away from the 50-day moving average of $6.78 and $-3.70 away from the 200-day moving average of $10.52. The stock has been recently noted at -50.15% off of the 52-week high of 13.68 and +18.40% separated from the 52-week low of 5.76. Monitoring the stock price relative to moving averages as well as 52 week highs and lows may help with the evaluation of future stock performance.
Analysts that track the company may use various metrics to aid with calculating target price predictions.
A frequently used metric is a company’s price to earnings ratio. This calculation is derived by dividing the current share price by the projected earnings per share. Trinity Biotech plc – American currently has a P/E Ratio of 51.28. Traders may also keep an eye on a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the expected future growth rate of the company. A PEG Ratio below one may represent that the company is undervalued. If the company’s PEG Ratio is higher than one, it may indicate that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The company has a current PEG Ratio of -0.23.